A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study

Patrick J. Loehrer, Lawrence H. Einhorn, Paul J. Elson, E. David Crawford, Philip Kuebler, Ian Tannock, Derek Raghavan, Robin Stuart-Harris, Michael F. Sarosdy, Bruce A. Lowe, Brent Blumenstein, Donald Trump

Research output: Contribution to journalArticle

763 Scopus citations

Abstract

Purpose: A prospective randomized trial was performed to determine if the addition of methotrexate, vinblastine, and doxorubicin to cisplatin (M-VAC) imparted a response rate or a survival advantage over single-agent cisplatin in patients with advanced urothelial carcinoma. Patients and Methods: From October 1984 through May 1989, 269 patients with advanced urothelial carcinoma were entered onto this international intergroup trial and randomized to receive intravenous (IV) cisplatin (70 mg/m2) alone or with methotrexate (30 mg/m2 on days 1, 15, 22), vinblastine (3 mg/m2 on days 2, 15, 22) plus doxorubicin (30 mg/m2 on day 2). Cycles were repeated every 28 days until tumor progression or a maximum of six cycles. There were 246 fully assessable patients of whom 126 were randomized to cisplatin alone and 120 were randomized to the M-VAC regimen. Results: As expected, the M-VAC regimen was associated with a greater toxicity, especially leukopenia, mucositis, granulocytopenic fever, and drug-related mortality. Response rates were superior for the M-VAC regimen compared with single-agent cisplatin (39% v 12%; P < .0001). Similarly, the progression-free survival (10.0 v 4.3 months) and overall survival (12.5 v 8.2 months) were significantly greater for the combined therapy arm. Conclusion: Although a more toxic regimen, we found M-VAC to be superior to single-agent cisplatin with respect to response rate, duration of remission, and overall survival in patients with advanced urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)1066-1073
Number of pages8
JournalJournal of Clinical Oncology
Volume10
Issue number7
DOIs
StatePublished - Jan 1 1992

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this